Reducing the Burden of Heart Failure in Japan With Dapagliflozin　- A Cost Offset Model (IMPLICATION HF).

ABSTRACT:

Background

Dapagliflozin is clinically beneficial in heart failure (HF). However, how these clinical benefits translate into economic burden reduction is unclear. With IMPLICATION HF, we projected the reductions in HF events and costs that would result from dapagliflozin use in Japan using a cost offset model.

Methods and results

The modeled population comprised symptomatic HF patients from the DAPA-HF and DELIVER trials. We compared the event incidences and associated costs between HF treatment with and without dapagliflozin, using the prevalence, event rates, and event costs of HF in Japan from published literature, as well as the treatment effects of dapagliflozin from the pooled meta-analysis of DAPA-HF and DELIVER. The cumulative number of events (HF hospitalization [hH

SUBMITTER: Kishi T 

PROVIDER: S-EPMC12148354 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature